Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
Executive Summary
Phase I/II data for Glaxo’s BRAF/MEK combination of dabrafenib and trametinib, both pending FDA approval as single agents, suggest compelling efficacy. The combination may see off-label use if the drugs are approved as monotherapies, though payment could be a big hurdle.
You may also be interested in...
MEK/BRAF Combo Rests On Survival Benefit
The best positioning of GSK’s Tafinlar/Mekinist combo is still in flux as data continues to emerge in the rapidly evolving melanoma space.
GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
At a time when $10,000-per-month pricing is the norm in oncology, GSK has priced its just-approved BRAF inhibitor Tafinlar at $7,600, on the lower end by today’s standards. Company says it is planning to file the combination of Tafinlar with Mekinist – also just approved by FDA – in a matter of weeks in the U.S.
Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
Glaxo’s BRAF inhibitor dabrafenib and MEK inhibitor trametinib were approved as single agents for advanced melanoma, but the real promise lies in combination therapy for better efficacy and safety. Labeling for trametinib notes it is not indicated in patients who have already received BRAF therapy.